The data of MARCH ( Metformin and AcaRbose in Chinese as the initial Hypoglycaemic treatment ) trial demonstrated that acarbose and metformin have similar efficacy as initial therapy for hemoglobin A1c ( HbA1c ) reduction in Chinese patients with newly diagnosed type 2 diabetes .